This new legislation allows patients and their physicians in Florida to access non-FDA-approved autologous stem cell ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem cell transplantation.

Just when we thought we had enough on our medical to-do list-Pap smears, mammograms, cholesterol checks, stress management, ...

New drugs that target "zombie" tuberculosis (TB) cells are now a step closer, thanks to a new study led by the University of ...

Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the ...

In a recent study, Associate Professor Makoto Ikeya (Department of Clinical Application) and his team of researchers ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

Paul Little, CEO of biotech firm Vesper Bio, has heard of people aged 29 being told they have FTD, a rare form of dementia ...

Alzheimer's disease (AD) is a common, debilitating neurodegenerative disease affecting about 10% of people over the age of 65 ...

A war weapon used in World War One went on to become a key component in treating blood cancer with chemotherapy ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to big pharma, too, in terms of restructuring and refocusing – even in terms of ...